Meet Our Team
Lindis Blood Care was founded by Dr. Horst Lindhofer, who was the developer of the first trifunktional antibody that was approved in Europe, Canada and Russia, and Dr. Franzpeter Bracht, who has extensive experience in setting up new companies and Business Development.
11.1997 Head of Clinical Co-operation Group “bispecific antibodies in tumour therapy” of the Department of Otorhinolaryngology, LMU Munich, and GSF Institute of Clinical Molecular Biology and Tumour Genetics, Munich
1994 New Investigator Award on the occasion of the 23rd ISEH Congress (International Society of Experimental Hematology), Minneapolis, USA for the development of a new manufacturing process of bispecific antibodies and first results in in vivo therapy
11.1992 – 11.1997 Research Scientist at GSF Institute for Immunology, Department of Hematology, University Hospital Munich- Großhadern; Team leader “bispecific antibodies and tumour immunotherapy”
09.1989 – 09.1992 Ph.D. Student, Max-von-Pettenkofer Institute, Ludwig-Maximilians- University (LMU), Munich
Title of Ph.D. thesis: “Examination on maturation and assembly of HIV-1 with specific antibodies”
1983 – 1989 Study of Biology, Ludwig-Maximilians-University (LMU), Munich
Dr. Horst Lindhofer is the founder and Chief Executive Officer of LINDIS Biotech GmbH and TRION Research GmbH and. He was also the founder and Chief Executive Officer of TRION Pharma GmbH.
He studied Biology at Ludwig-Maximilians-University (LMU), Munich (Diploma) and did his PhD at Max-von- Pettenkofer Institute, Ludwig-Maximilians-University (LMU), Munich. Title of PhD thesis: “Examination on maturation and assembly of HIV-1 with specific antibodies”.
Dr. Lindhofer worked at the Helmholtz Zentrum München (1992 – 1997) as Head of a clinical cooperation group “bispecific antibodies” together with Munich’s University Hospital. He started his academic work with the improvement of existing bispecific antibody approaches and laid the foundation for the development of the triomab® concept towards an innovative and modular platform technology.
Resulting from the encouraging results of these studies he founded TRION Pharma GmbH and TRION Research GmbH in 1998 and LINDIS Biotech GmbH in 2010. All companies are located in or near Munich.
Dr. Lindhofer is author of more than 50 publications, developer of numerous patents in the field of immunotherapy and received several international awards.
The Next Step in
CATUVAB – a MEDIVAL DEVICE to remove cancer cells from blood.